Paradigm Biocapital Advisors LP Immunocore Holdings PLC Transaction History

Paradigm Biocapital Advisors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$60.14 - $75.36 $20 Million - $25.1 Million	333,293 Added 22.92%	1,787,176 $116 Million
Q4 2023 Feb 14, 2024	BUY	$42.85 - $69.5 $2.97 Million - $4.81 Million	69,197 Added 5.0%	1,453,883 $99.3 Million
Q3 2023 Nov 14, 2023	BUY	$49.5 - $66.6 $5.67 Million - $7.63 Million	114,562 Added 9.02%	1,384,686 $71.9 Million
Q2 2023 Aug 14, 2023	BUY	$48.54 - $61.64 $6.98 Million - $8.87 Million	143,868 Added 12.77%	1,270,124 $76.2 Million
Q1 2023 May 15, 2023	BUY	$46.12 - $65.71 $12.4 Million - $17.6 Million	268,331 Added 31.28%	1,126,256 $55.7 Million
Q4 2022 Feb 14, 2023	BUY	$45.51 - $65.08 $3.86 Million - $5.52 Million	84,846 Added 10.98%	857,925 $49 Million
Q3 2022 Nov 14, 2022	BUY	$37.34 - $57.44 $3.95 Million - $6.07 Million	105,662 Added 15.83%	773,079 $36.3 Million
Q2 2022 Aug 15, 2022	BUY	$25.46 - $37.72 $4.28 Million - $6.35 Million	168,227 Added 33.7%	667,417 $24.9 Million
Q1 2022 May 16, 2022	BUY	$18.94 - $34.29 $6.91 Million - $12.5 Million	364,941 Added 271.84%	499,190 $14.9 Million
Q4 2021 Feb 14, 2022	BUY	$27.58 - $40.0 $3.7 Million - $5.37 Million	134,249 New	134,249 $4.6 Million

141

41.4M

197K

451K

Ticker IMCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,897,100
Market Cap $1.24B
Description
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.